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Abstract
Background: Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most
common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to
primary PCP prophylaxis.
Methodology/Principal Findings: We used 2000–2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a
cross-sectional interview project of HIV-infected persons $18 years conducted in 18 states. We limited the analysis to
persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question
‘‘In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take
them?’’ We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects
prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported
using marijuana (adjusted odds ratio [aOR]=1.6, 95% confidence interval [CI]=1.1–2.4), non-injection drugs other than
marijuana (aOR=1.5, 95% CI=1.0–2.1), or injection drugs (aOR=2.3, 95% CI=1.3–4.1) in the past year; their mental health
was ‘‘not good’’ for $1 day during the past month (aOR=1.6, 95% CI=1.2–2.2); their most recent CD4 count was ,200
cells/mL (aOR=1.6, 95% CI=1.1–2.2); or taking ART usually (aOR=9.6, 95% CI=6.7–13.7) or sometimes/rarely/never
(aOR=18.4, 95% CI=11.1–30.4), compared with always, as prescribed.
Conclusion/Significance: Providers should inquire about and promote strategies to improve adherence to PCP prophylaxis,
particularly among persons who use illicit drugs, have mental health issues, and who are not compliant with ART to reduce
the occurrence of PCP.
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Introduction
Pneumocystis jirovecii pneumonia (PCP) continues to be the most
common serious opportunistic infection occurring among persons
with HIV infection in the United States despite effective
prophylactic therapy [1]. During the 1980s, PCP was the AIDS-
defining illness for approximately two-thirds of patients, and it was
estimated that 75% of HIV-infected persons would develop PCP
in their lifetime [2,3]. Trimethoprim-sulfamethoxazole (TMP-
SMX) was shown to be effective in preventing PCP in persons with
AIDS in the late 1980s [4], and the proportion of cases in which
PCP was an AIDS-defining illness decreased appreciably as
prescription of TMP-SMX to prevent PCP became the standard
of care [5,6]. The widespread use of antiretroviral therapy (ART)
in the late 1990s led to a further decline in the incidence of PCP
[3]. Current Centers for Disease Control and Prevention (CDC)
guidelines recommend the initiation of primary PCP prophylaxis
for persons with CD4 cell counts less than 200 cells/mLo ra
history of oropharyngeal candidiasis, and discontinuation of
prophylaxis for persons who have responded to ART with an
increase in CD4 cell counts to more than 200 cells/mL for greater
than 3 months [7].
Although prophylaxis against PCP is effective, the benefits can
only be realized if HIV-positive persons access healthcare,
providers appropriately prescribe prophylaxis to persons at risk
for PCP, and patients adhere to prescribed PCP prophylaxis. In an
analysis of PCP cases diagnosed during 1999–2001, 44% of cases
occurred among persons not receiving care, 10% occurred among
persons in care who met criteria for prophylaxis but were not
prescribed prophylaxis, and 41% occurred among persons
prescribed prophylaxis but who were either not adherent to
treatment or who developed PCP despite appropriate use [3]. The
U.S. Healthy People 2010 goal is for 95% of eligible persons to
receive PCP prophylaxis [8]. The proportion of eligible persons
prescribed PCP prophylaxis in a large U.S. cohort of HIV-positive
persons was 80% [9], whereas in another study, the proportion of
providers who adhered with guidelines for prescribing PCP
prophylaxis in federally funded HIV treatment facilities ranged
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nonadherence to prophylaxis guidelines was uncommon and that
patient nonadherence to prophylaxis was the most common
reason for the occurrence of PCP [11]. Few studies have examined
patient adherence to PCP prophylaxis and reasons for nonadher-
ence. In one study, only 49% of persons reported taking at least
80% of their prescribed PCP prophylaxis in the previous seven
days [12]. Presence of family, better mental health, and greater
self-efficacy were associated with increased adherence to PCP
prophylaxis, whereas injection drug use was associated with
nonadherence [12].
The objective of this analysis was to identify factors associated
with and self-reported reasons for nonadherence to primary PCP
prophylaxis among HIV-infected persons.
Methods
Project
The Supplement to HIV and AIDS Surveillance (SHAS) project
was a cross-sectional behavioral surveillance project of persons
with HIV infection. The methods have been previously described
[13]. In brief, adults ($18 years) reported with HIV or AIDS
through routine case surveillance were eligible for participation.
Persons with HIV/AIDS were enrolled using one of two methods:
1) facility-based recruitment of all eligible persons seeking
treatment at selected healthcare facilities in 13 cities in 9 states
(Denver, Colorado; Hartford and New Haven, Connecticut;
Jacksonville, Miami, and Tampa, Florida; Atlanta, Georgia;
Chicago, Illinois; Baltimore, Maryland; Detroit, Michigan; Jersey
City and Paterson, New Jersey; and Philadelphia, Pennsylvania);
and 2) population-based recruitment of all eligible persons in 5
states and in 6 cities and one county in four additional states
(Phoenix and Tucson, Arizona; Delaware; Kansas; Los Angeles
County, California; Minneapolis/St. Paul, Minnesota; New
Mexico; South Carolina; Austin and Houston Texas; and
Washington). Most SHAS participants were enrolled in the
project soon after they began to receive care for HIV infection.
Informed consent was obtained by having the participant read and
sign the informed consent form, having the interviewer read the
form to the participant and asking the participant to sign the form,
or having the interviewer read the form to the participant and
indicating on the form that participant provided verbal consent.
The project received institutional review board approval at both
the CDC and local levels.
Measures
From May 2000 through June 2004, SHAS participants were
asked about medication history, adherence to medications, and
reasons for nonadherence. SHAS has no way to measure
adherence with medications independently, but instead relies on
self-reported adherence. To determine if respondents were taking
PCP prophylaxis and the specific medication(s), they were asked to
look at a list of PCP medications on a card. After indicating those
medications that were ever prescribed to them, they were asked to
indicate which ones they were currently taking. Because there
were no questions that specifically addressed whether respondents
were taking PCP in this analysis because survey questions did not
allow us to determine whether a current prescription for PCP
medication was for treatment or secondary prophylaxis against
PCP. We limited our analysis to persons who answered the
question ‘‘Sometimes it is difficult to take medications for many
reasons. In the past 30 days, how often were you able to take your
PCP medication(s) exactly the way your doctor told you to take
them?’’ Persons answering ‘‘always’’ were considered adherent
and those answering ‘‘usually’’, ‘‘sometimes’’, or ‘‘rarely or never’’
were considered nonadherent to PCP prophylaxis; persons
answering ‘‘unknown’’ to this question and those who did not
answer this question were excluded from the analysis because we
did not have complete information about their adherence to PCP
prophylaxis. Nonadherent persons were asked about the primary
reason for nonadherence by asking, ‘‘What are some of the reasons
why you don’t take your PCP medicine(s) as the doctor
prescribed?’’ Respondents were able to provide as many as three
reasons for nonadherence. We coded the responses into three
categories: 1) side effects; 2) difficulties with access to care or
obtaining/taking medications; and 3) problems with scheduling,
memory, or lack of perceived necessity. Region of residence was
defined by the U.S. Census Bureau. Risk for recent alcohol abuse
was defined as answering ‘‘yes’’ to two or more CAGE questions
[14] and reporting alcohol use in the previous year. The daily pill
burden was calculated by adding the number of medications
prescribed for ART, prophylaxis against opportunistic infections,
and other conditions. Assessment of mental health during the
previous month was determined by the answer to the question,
‘‘Now thinking about your mental health, which includes stress,
depression, and problems with emotions, for how many days
during the past 30 days was your mental health not good?’’
Respondents were asked to look at a list of ‘‘HIV/AIDS
medicines’’ (ART medications) and tell the interviewer which of
the listed medications they had ever taken and which they were
currently taking. Adherence to ART was defined for persons who
reported having a current prescription for ART and who
answered the question ‘‘In the past 30 days, how often were you
able to take your HIV/AIDS medicines exactly the way your
doctor told you to take them?’’ Persons could answer ‘‘always’’,
‘‘usually’’, ‘‘sometimes’’, ‘‘rarely or never’’, or ‘‘unknown’’, and
their adherence to ART medicines was categorized accordingly,
although those answering ‘‘sometimes’’ or ‘‘rarely or never’’ were
grouped together for this analysis. Illicit drug use was categorized
as no drug use, use of marijuana only, use of non-injection drugs
other than marijuana, and use of injection drugs in the past year.
In addition, for some analyses, injection drug use was categorized
as injection drug use versus no injection drug use in the past year.
Analyses
Statistical testing for differences (p,0.05) between factors
associated with adherence and nonadherence to PCP prophylaxis
was performed using chi-squared or Fisher’s exact test, as
appropriate. We used multivariable logistic regression models
using STATA version 8.0 (STATA Corporation, Corpus Christi,
TX) to calculate adjusted odds ratios and 95% confidence intervals
for factors associated with nonadherence to PCP prophylaxis.
Because region of residence and year of SHAS interview were
identified as likely confounding factors of nonadherence to PCP
prophylaxis a priori, these variables were included in all
multivariable models. In multivariable analyses, controlling for
region of residence and year of SHAS interview, preliminary
models included factors that were associated (p#0.10) with
nonadherence to primary PCP prophylaxis in bivariate analyses.
We performed stepwise elimination to remove factors that were
not significantly associated (p.0.05) with nonadherence [15]. We
assessed all possible two-way interactions between variables using a
forward selection model using SAS version 9.1 (SAS Institute,
Cary, NC), with a p-value for entry that was corrected for multiple
comparisons between the number of possible interaction terms.
We conducted a sensitivity analysis using a more restrictive
definition of nonadherence (having only sometimes, rarely, or
never taken PCP medications exactly as prescribed during the past
PCP Prophylaxis Nonadherence
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prophylaxis is a low CD4 cell count, we also conducted
multivariable analysis after restricting the data set to persons with
CD4 counts less than 200 cells/mL.
Results
Of the 11,503 persons asked to participate in SHAS, 1,666
(18.3% of interviewed) respondents who had a prescription for
primary PCP prophylaxis and complete information about
adherence to PCP prophylaxis were included in the analysis.
Eligibility and selection criteria for subjects included in this
analysis of nonadherence to PCP prophylaxis are summarized in
Figure 1. Among these 1,666 persons, 76.8% were male, 75.4%
considered themselves to be non-Hispanic black or Hispanic, and
the median age was 40 (range: 19–75) years. Seventy-nine percent
of subjects who reported having a current prescription for PCP
medications were prescribed TMP-SMX.
Three hundred five (18.3%) respondents were nonadherent with
primary PCP prophylaxis during the month preceding their
interview. On bivariate analysis, nonadherence to primary PCP
prophylaxis was associated with year of SHAS interview, illicit
drug use in the past year, current risk for alcohol abuse,
description of mental health as ‘‘not good’’ for $1 day in the
past month, most recent CD4 count ,200 cells/mL, most recent
HIV viral load .5,000 copies/mL, and nonadherence to ART in
the past month (Table 1). Sex, age group, race/ethnicity, income,
having health insurance, education, U.S. region of residence,
living situation, current PCP medication(s) prescribed, daily pill
burden, and type of recruitment were not associated with
nonadherence to PCP prophylaxis.
Multivariable analysis was performed to identify factors that
were independently associated with nonadherence to primary PCP
prophylaxis. Controlling for region of residence and year of
interview, factors that were independently associated with
nonadherence to primary PCP prophylaxis were use of marijuana,
non-injection drugs other than marijuana, and injection drugs in
the past year; description of mental health as not good for $1 day
in the past month; most recent CD4 count ,200 cells/mL; and
having taken ART usually or sometimes/rarely/never as pre-
scribed, having taken ART but having unknown or missing
information about adherence to ART, or not having taken ART in
the past month (Table 2). No significant interaction was found.
The risk of nonadherence to PCP prophylaxis increased with the
level of nonadherence to ART, being approximately twice as high
among persons who reported having sometimes/rarely/never
been adherent with ART as it was among those who reported
having usually been adherent with ART during the preceding
month.
Limiting the multivariable analysis to persons whose most
recent CD4 count was ,200 cells/mL and controlling for region of
residence and year of interview, injection drug use in the past year
Figure 1. Eligibility and selection criteria for subjects included in this analysis of nonadherence to Pneumocystis jirovecii pneumonia
(PCP) prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.
doi:10.1371/journal.pone.0005002.g001
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prescribed primary prophylaxis against Pneumocystis jirovecii
pneumonia (PCP), by nonadherence to prophylaxis –
Supplement to HIV/AIDS Surveillance(SHAS) project, 2000–2004.
Characteristics Primary PCP Prophylaxis
Nonadherent* Adherent*
N=305 N=1,361
n( % ) n( % )
Year of SHAS interview{
2000 45 (14.7) 111 (8.2)
2001 82 (26.9) 407 (29.9)
2002 93 (30.5) 411 (30.2)
2003 60 (19.7) 333 (24.5)
2004 25 (8.2) 99 (7.3)
Sex
Male 240 (78.7) 1040 (76.4)
Female 65 (21.3) 321 (23.6)
Race/Ethnicity
White, non-Hispanic 67 (22.0) 273 (20.1)
Black, non-Hispanic 179 (58.7) 762 (56.6)
Hispanic 46 (15.1) 269 (19.8)
Other 13 (4.3) 57 (4.7)
Age group (years)
18–29 38 (12.5) 126 (9.3)
30–39 112 (40.0) 498 (36.6)
40–49 113 (37.0) 550 (40.4)
$50 32 (10.5) 187 (13.7)
Employed
Yes 92 (30.2) 383 (28.1)
No 213 (69.8) 978 (71.9)
Current annual income
,$10,000 161 (57.8) 666 (48.9)
$10,000–20,000 53 (17.4) 265 (19.5)
$$20,000 70 (22.9) 322 (23.7)
Unknown or refused to answer 21 (6.9) 108 (7.9)
Education
,High school/General Equivalency
Diploma (GED)
94 (30.8) 446 (32.8)
High school/GED 95 (31.1) 433 (31.8)
.High school/GED 116 (38.0) 482 (35.4)
Medical insurance
Yes 240 (78.7) 1,075 (79.0)
No 65 (21.3) 286 (21.0)
Region of residence{
Northeast 25 (8.2) 73 (5.4)
South 155 (50.8) 728 (53.5)
Midwest 48 (15.7) 212 (15.6)
West 77 (25.2) 348 (25.6)
Current living situation
Alone 100 (32.8) 403 (29.6)
With partner, family, or friend 172 (56.4) 837 (61.5)
In a medical facility 10 (3.3) 42 (3.1)
In shelter 15 (4.9) 47 (3.4)
Other6 8 (2.6) 32 (2.3)
Characteristics Primary PCP Prophylaxis
Nonadherent* Adherent*
N=305 N=1,361
n( % ) n( % )
Illicit drug use in past year1{
No 142 (46.6) 899 (66.0)
Marijuana only 54 (17.7) 179 (13.1)
Non-injection drugs other than marijuana 81 (26.6) 233 (17.1)
Injection drug use 28 (9.2) 50 (3.7)
Risk for alcoholism||{
Yes 103 (33.8) 328 (24.1)
No 202 (66.2) 1.033 (75.9)
Mental health described as not good $1 day
during the last month{
Yes 232 (76.1) 821 (60.3)
No 73 (23.9) 540 (39.7)
Recent CD4 count (cells/mL){
,200 160 (52.5) 536 (39.4)
$200 77 (25.2) 393 (28.9)
Unknown/missing 68 (22.3) 432 (31.7)
Viral load (copies/mL){
#5000 108 (35.4) 525 (38.6)
.5,000 74 (24.3) 240 (17.6)
Unknown/missing 123 (40.3) 596 (43.8)
Current PCP medication prescribed
Trimethoprim-sulfamethoxazole 243 (79.7) 1078 (79.2)
Dapsone 37 (12.1) 169 (12.4)
Other/unknown 25 (8.2) 114 (8.4)
Antiretroviral therapy (ART) in the past
month{
On ART, always adherent 59 (19.3) 910 (66.9)
On ART, usually adherent 125 (41.0) 194 (14.2)
On ART, sometimes, rarely, or never
adherent
59 (19.3) 44 (3.2)
On ART, unknown or missing information
about adherence
20 (6.6) 104 (7.6)
Not on ART 42 (13.8) 109 (8.0)
Total number of pills prescribed for daily use
1–3 87 (28.5) 371 (27.3)
4–5 120 (39.3) 515 (37.8)
$6 98 (32.1) 475 (34.9)
Recruitment type
Facility-based 192 (62.9) 894 (65.7)
Population-based 113 (37.0) 467 (34.3)
*Column percentages may not total 100% because of rounding.
{P-value ,0.05 when comparing persons nonadherent with those adherent to
PCP prophylaxis.
{Regions defined by U.S. Census Bureau; for SHAS sites included in this analysis,
Northeast comprises NJ, CT, and PA; South comprises GA, MD, FL, SC, DE, and
TX; Midwest comprises IL, KS, MI, and MN; and West comprises AZ, CA, CO, NM,
and WA.
6Other responses included correctional institution, refused to answer, and
other responses which did not fit into the listed response categories.
1Categories are mutually exclusive.
||Defined as answering yes to at least 2 of the CAGE screening questions and
reporting alcohol use in the past year.
doi:10.1371/journal.pone.0005002.t001
Table 1. cont.
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1.1–4.9) and having taken ART usually (aOR: 9.2; 95% CI: 5.5–
15.5) or sometimes/rarely/never (aOR: 26.8; 95% CI: 13.1–54.5)
as prescribed, having taken ART but having unknown or missing
information about adherence to ART (aOR: 2.6; 95% CI: 1.2–
5.3), or not having taken ART (aOR: 4.8; 95% CI: 2.6–9.1) in the
past month were independently associated with nonadherence to
primary PCP prophylaxis. The risk of nonadherence to PCP
prophylaxis was almost three times as high among persons who
reported having sometimes/rarely/never been adherent with
ART as it was among those who reported having usually been
adherent with ART during the preceding month.
When we used the more restrictive definition of nonadherence
to PCP prophylaxis during the past month (i.e., defining it as
taking PCP medications sometimes, rarely, or never), our findings
on multivariable analysis did not change appreciably (data not
shown). However, description of mental health as not good for $1
day in the past month did not remain in the model and injection
drug use during the past year was no longer an independent risk
factor for nonadherence using the more restrictive definition of
nonadherence.
Of the 305 persons who reported that they did not take primary
PCP prophylaxis exactly as prescribed during the month before
interview, 264 (86.6%) reported the primary reason why they did
not do so. Side effects were cited by 21.6%; difficulties with access
to care or obtaining/taking medications were reported by 13.6%;
and problems with scheduling, difficulty remembering to take the
medication(s), or lack of perceived necessity were listed by 64.8%
of subjects (Table 3). The most common reason cited for not
taking PCP prophylaxis was forgetting to take it.
Discussion
In a large cohort of persons living with HIV infection, we found
that almost one-fifth were nonadherent to primary PCP prophylaxis.
Wefoundthatnonadherence to PCPprophylaxiswasassociatedwith
illicit drug use, mental health issues including depression, nonadher-
ence to prescribed ART, and low CD4 cell count.
Our findings regarding illicit drug use are consistent with those
of several studies evaluating adherence to ART
[16,17,18,19,20,21,22,23], however current drug use was not
found to be an independent risk factor in either study evaluating
risk factors for nonadherence to PCP prophylaxis [11,12]. We did
not find nonadherence to be associated with age, race/ethnicity,
or daily pill burden, factors which have previously been reported
to be associated with increased risk for nonadherence to PCP
prophylaxis and/or ART.
Consistent with our findings, Eldred and colleagues found that a
high Mental Health Inventory-5 score, which indicates better
mental health, was associated with adherence to PCP prophylaxis
[12]. Lundberg and colleagues found that persons with current
psychiatric illness were more likely to be nonadherent to PCP
prophylaxis; however they did not find this condition to be an
independent risk factorfornonadherence[11]. Additionally, mental
health issues have been associated with nonadherence to ART in
several studies [16,23,24,25,26]. It is possible, though, that persons
with better mental health may report adherence to medications
more accurately than persons with poorer mental health.
Persons who reported being nonadherent to primary PCP
prophylaxis were much more likely to report also being
nonadherent to ART, which is consistent with the findings of
Lundberg and associates [11]. We found that the risk of
nonadherence to PCP prophylaxis was highest among those with
the highest levels of reported nonadherence to ART medications.
We found that low CD4 cell count was independently associated
with nonadherence to PCP prophylaxis. However, 29% of
respondents reported having recent CD4 cell counts that were
$200 cells/mL, and 32% could not provide information about
their most recent CD4 cell count. Respondents whose most recent
CD4 cell counts were $200 cells/mL may have been started on
PCP prophylaxis based on a declining trend in CD4 cell counts,
may not have had CD4 cell counts that were $200 cells/mL for at
least 3 months, or may not have accurately recalled their most
recent CD4 count. When we limited our analysis to persons who
reported that their most recent CD4 cell count was ,200 cells/mL,
our findings did not change appreciably. Among subjects reporting
they had a CD4 count ,200 cells/mL, recent injection drug use
and nonadherence to ART remained independent predictors for
nonadherence to PCP prophylaxis; however, non-injection drug
use did not remain an independent risk factor.
Although several studies have found that nonadherence to PCP
prophylaxis and/or ART was associated with age [19,23,24,25] or
race/ethnicity [11,23], we did not find nonadherence to PCP
prophylaxis to be independently associated with these or other
sociodemographic characteristics. In addition, we found that daily
pill burden was not associated with nonadherence to PCP
prophylaxis, which contradicts the findings of several studies that
have found that an increased number of ART pills taken daily is
Table 2. Multivariable analysis of factors associated with
nonadherence to primary prophylaxis against Pneumocystis
jirovecii pneumonia (PCP) – Supplement to HIV/AIDS
Surveillance (SHAS) project, 2000–2004.
Characteristics
Adjusted Odds
Ratio (95%
Confidence
Interval)*
N=1,666
Illicit drug use in last year
No Reference
Marijuana only 1.6 (1.1–2.4)
Non-injection drugs other than marijuana 1.5 (1.0–2.1){
Injection drug use 2.3 (1.3–4.1)
Number of days mental health described as not
good last month
0 Reference
$1 1.6 (1.2–2.2)
Recent CD4 count (cells/mL)
,200 1.6 (1.1–2.2)
$200 Reference
Unknown/missing 0.9 (0.6–1.4)
Antiretroviral therapy (ART) in the past month
On ART, always adherent Reference
On ART, usually adherent 9.6 (6.7–13.7)
On ART, sometimes, rarely, or never adherent 18.4 (11.1–30.4)
On ART, unknown or missing information
about adherence
2.7 (1.5–4.7)
Not taking ART 5.1 (3.3–8.1)
*In addition to adjusting for variables included in this table, we controlled for
region of residence in the U.S. and year of SHAS interview.
{P-value,0.05.
doi:10.1371/journal.pone.0005002.t002
PCP Prophylaxis Nonadherence
PLoS ONE | www.plosone.org 5 March 2009 | Volume 4 | Issue 3 | e5002associated with nonadherence to PCP prophylaxis or ART
[11,23,24]. Our findings may differ from those of other
investigators because we were able to control more completely
for potentially confounding variables or, with respect to the
number of pills taken daily, because we used a different measure
for pill burden that included all medications prescribed and not
just ART medications.
Forgetting to take PCP prophylaxis was the most common
reason provided by participants in our analysis, followed by
concern about side effects and inability to fit taking the
medication(s) into one’s schedule, which parallels reasons given
for nonadherence to ART among SHAS participants in a separate
analysis [23]. Forgetting to take medications has previously been
reported to be an important reason for nonadherence to PCP
prophylaxis [11], ART [27], and prescribed therapy for other
conditions [28,29]. Structural barriers such as limited access to
healthcare or medications were not prominent as reasons for
nonadherence in our analysis.
This study has several imitations. Because this was an interview
study, our findings are subject to recall and social desirability bias
[30]. However, asking subjects about their adherence to primary
PCP prophylaxis in the month before the interview should have
reduced recall bias. Because social desirability would be expected
to lead subjects to underreport nonadherence to medications, our
estimate may be a minimum one [31]. Because hospitals that
participated in areas which used facility-based recruitment may
not have been representative of all facilities that provide care to
HIV-infected persons in these areas, and persons recruited and
interviewed by SHAS sites were not representative of all HIV-
infected persons, or of all HIV-infected persons in care, our
findings are subject to selection bias. In addition, limited or no
information was collected in the interview about a number of
factors that may be important for nonadherence, including social
support, isolation, treatment efficacy, and self-efficacy [32,33].
Despite these limitations, the SHAS surveillance system represents
the largest survey of HIV-infected persons in the U.S. and
therefore has the most complete data to assess self-reported
adherence to PCP prophylaxis.
Nonadherence to PCP prophylaxis is an important contributor
to adverse clinical events, and nonadherence to relatively simple
regimens used to protect against PCP suggests that there may be
greater challenges with adherence to ART regimens, which are
more complicated [11]. We found that an appreciable proportion
of HIV-infected persons were nonadherent to prescribed medica-
tions to prevent PCP, and that persons who were nonadherent to
PCP prophylaxis were much more likely to be nonadherent to
ART. Providers should inquire about adherence to prescribed
medications to prevent PCP at every HIV care visit, paying
particular attention to persons who use illicit drugs, have mental
health issues, have low CD4 cell counts, and are nonadherent to
ART or medications prescribed for other conditions. These
variables should be triggers for providers to consider the complex
issue of adherence. Providers should take every opportunity to
educate their patients about the importance of compliance with
ART and medications to prevent opportunistic infections, discuss
the possible side effects of prescribed medications, and assist
patients about ways to remember to take their medications as
prescribed. In addition, providers should regularly ask HIV-
infected patients about illicit drug use and mental health issues and
treat or refer persons with substance abuse and/or mental illnesses
to ensure optimal adherence to prescribed medications. Although
few studies have evaluated factors associated with nonadherence
or ways to improve adherence to medications to prevent PCP, the
commonality of associated factors for nonadherence to PCP
prophylaxis and ART suggests that interventions for ART
adherence may be also be used to improve adherence to PCP
prophylaxis. Studies evaluating adherence to ART, prophylaxis
against PCP and other opportunistic infections, and prescribed
medications for other conditions may shed light on how to
improve adherence and quality of life and reduce morbidity and
mortality among HIV-infected persons.
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